Modality
Multispecific
MOA
STINGag
Target
SOS1
Pathway
Proteasome
DMD
Development Pipeline
Preclinical
~Jul 2021
→ ~Oct 2022
Phase 1
Jan 2023
→ Sep 2030
Phase 1Current
NCT04106472
1,008 pts·DMD
2023-01→2030-09·Active
1,008 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-044.4y awayPh2 Data· DMD
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Active
Catalysts
Ph2 Data
2030-09-04 · 4.4y away
DMD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04106472 | Phase 1/2 | DMD | Active | 1008 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |